JP7330896B2 - 抗ｔｓｌｐ抗体による喘息治療 - Google Patents

抗ｔｓｌｐ抗体による喘息治療 Download PDF

Info

Publication number
JP7330896B2
JP7330896B2 JP2019555854A JP2019555854A JP7330896B2 JP 7330896 B2 JP7330896 B2 JP 7330896B2 JP 2019555854 A JP2019555854 A JP 2019555854A JP 2019555854 A JP2019555854 A JP 2019555854A JP 7330896 B2 JP7330896 B2 JP 7330896B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
tslp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019555854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516647A (ja
JP2020516647A5 (OSRAM
JPWO2018191479A5 (OSRAM
Inventor
ジェーン アール． パーネス，
ジャネット グリフィス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2020516647A publication Critical patent/JP2020516647A/ja
Publication of JP2020516647A5 publication Critical patent/JP2020516647A5/ja
Publication of JPWO2018191479A5 publication Critical patent/JPWO2018191479A5/ja
Priority to JP2023080295A priority Critical patent/JP2023099233A/ja
Application granted granted Critical
Publication of JP7330896B2 publication Critical patent/JP7330896B2/ja
Priority to JP2024127900A priority patent/JP2024150751A/ja
Priority to JP2025147176A priority patent/JP2025170430A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019555854A 2017-04-12 2018-04-12 抗ｔｓｌｐ抗体による喘息治療 Active JP7330896B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023080295A JP2023099233A (ja) 2017-04-12 2023-05-15 抗ｔｓｌｐ抗体による喘息治療
JP2024127900A JP2024150751A (ja) 2017-04-12 2024-08-02 抗ｔｓｌｐ抗体による喘息治療
JP2025147176A JP2025170430A (ja) 2017-04-12 2025-09-04 抗ｔｓｌｐ抗体による喘息治療

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US62/484,864 2017-04-12
US201762553477P 2017-09-01 2017-09-01
US201762553575P 2017-09-01 2017-09-01
US62/553,575 2017-09-01
US62/553,477 2017-09-01
PCT/US2018/027271 WO2018191479A1 (en) 2017-04-12 2018-04-12 Treatment of asthma with anti-tslp antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023080295A Division JP2023099233A (ja) 2017-04-12 2023-05-15 抗ｔｓｌｐ抗体による喘息治療

Publications (4)

Publication Number Publication Date
JP2020516647A JP2020516647A (ja) 2020-06-11
JP2020516647A5 JP2020516647A5 (OSRAM) 2021-05-20
JPWO2018191479A5 JPWO2018191479A5 (OSRAM) 2022-11-22
JP7330896B2 true JP7330896B2 (ja) 2023-08-22

Family

ID=62092313

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019555854A Active JP7330896B2 (ja) 2017-04-12 2018-04-12 抗ｔｓｌｐ抗体による喘息治療
JP2023080295A Withdrawn JP2023099233A (ja) 2017-04-12 2023-05-15 抗ｔｓｌｐ抗体による喘息治療
JP2024127900A Pending JP2024150751A (ja) 2017-04-12 2024-08-02 抗ｔｓｌｐ抗体による喘息治療
JP2025147176A Pending JP2025170430A (ja) 2017-04-12 2025-09-04 抗ｔｓｌｐ抗体による喘息治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023080295A Withdrawn JP2023099233A (ja) 2017-04-12 2023-05-15 抗ｔｓｌｐ抗体による喘息治療
JP2024127900A Pending JP2024150751A (ja) 2017-04-12 2024-08-02 抗ｔｓｌｐ抗体による喘息治療
JP2025147176A Pending JP2025170430A (ja) 2017-04-12 2025-09-04 抗ｔｓｌｐ抗体による喘息治療

Country Status (21)

Country Link
US (3) US10828365B2 (OSRAM)
EP (1) EP3609917A1 (OSRAM)
JP (4) JP7330896B2 (OSRAM)
KR (2) KR20240070727A (OSRAM)
CN (1) CN110573525A (OSRAM)
AU (2) AU2018253118B2 (OSRAM)
BR (1) BR112019021482A2 (OSRAM)
CA (1) CA3059364A1 (OSRAM)
CL (1) CL2019002897A1 (OSRAM)
CO (1) CO2019011462A2 (OSRAM)
IL (1) IL269791B (OSRAM)
JO (1) JOP20190243A1 (OSRAM)
MX (1) MX2019012158A (OSRAM)
MY (1) MY207509A (OSRAM)
PE (1) PE20200484A1 (OSRAM)
PH (1) PH12019502331A1 (OSRAM)
SG (1) SG11201909322VA (OSRAM)
TN (1) TN2019000289A1 (OSRAM)
TW (2) TWI856945B (OSRAM)
UY (1) UY37676A (OSRAM)
WO (1) WO2018191479A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023099233A (ja) * 2017-04-12 2023-07-11 アムジェン インコーポレイテッド 抗ｔｓｌｐ抗体による喘息治療

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61763B1 (sr) * 2015-09-09 2021-05-31 Novartis Ag Antitela koja vezuju timusni stromalni limfopoetin (tslp) i metode za korišćenje antitela
WO2020244544A1 (zh) * 2019-06-04 2020-12-10 江苏恒瑞医药股份有限公司 能结合胸腺基质淋巴细胞生成素的抗体及其应用
US12435131B2 (en) 2019-07-11 2025-10-07 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
CN117467007A (zh) * 2019-09-04 2024-01-30 正大天晴药业集团股份有限公司 结合tslp的抗体及其用途
UA129038C2 (uk) * 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
CN112876564B (zh) * 2019-11-29 2022-07-15 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
KR20220113673A (ko) * 2019-12-13 2022-08-16 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항-tslp 항체 및 그 용도
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US20230073888A1 (en) * 2020-02-13 2023-03-09 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
IL295042A (en) * 2020-02-13 2022-09-01 Amgen Inc Formulations of human anti-tslp antibodies and methods of treating inflammatory disease
AR121368A1 (es) * 2020-02-18 2022-06-01 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos
CN113388035A (zh) * 2020-03-13 2021-09-14 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
WO2022184074A1 (zh) * 2021-03-03 2022-09-09 正大天晴药业集团股份有限公司 含抗tslp抗体的药物组合物
PH12023552762A1 (en) * 2021-04-19 2024-04-15 Medimmune Ltd An anti-tslp fab with improved stability
KR20230175245A (ko) 2021-04-23 2023-12-29 암젠 인크 변형된 항-tslp 항체
MX2023012363A (es) 2021-04-23 2023-11-01 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas.
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117209604B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
UY40500A (es) 2022-10-26 2024-04-30 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
AR133648A1 (es) * 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos anti-tslp y sus usos
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
AR098155A1 (es) * 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos
SG11201700901SA (en) * 2014-08-08 2017-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
AU2016231122A1 (en) 2015-03-11 2017-09-07 Glaxosmithkline Intellectual Property Development Limited TSLP binding proteins
MY186352A (en) 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J. Allergy Clin. Immunol., 2018.2, Vol.141, No.2, Suppl., AB80, #257
N. Engl. J. Med., 2014, Vol.370, No.22, pp.2102-2110
N. Engl. J. Med., 2017.9, Vol.377, No.10, pp.936-946
Study NCT02054130 on Date: January 6, 2017 (v9)，ClinicalTrials.gov archive[online]，2017年1月6日，[2022年4月27日検索]，<URL: https://clinicaltrials.gov/ct2/history/NCT02054130>
Study NCT02512900 on Date: January 3, 2017 (v5)，ClinicalTrials.govarchive[online]，2017年1月3日，[2022年4月27日検索]，<URL: https://clinicaltrials.gov/ct2/history/NCT02512900>

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023099233A (ja) * 2017-04-12 2023-07-11 アムジェン インコーポレイテッド 抗ｔｓｌｐ抗体による喘息治療

Also Published As

Publication number Publication date
UY37676A (es) 2018-10-31
CN110573525A (zh) 2019-12-13
CO2019011462A2 (es) 2019-10-31
IL269791A (en) 2019-11-28
KR102666879B1 (ko) 2024-05-23
AU2018253118B2 (en) 2025-04-10
MX2019012158A (es) 2019-12-16
TW202523688A (zh) 2025-06-16
TWI856945B (zh) 2024-10-01
AU2018253118A1 (en) 2019-10-24
SG11201909322VA (en) 2019-11-28
TW201838652A (zh) 2018-11-01
JOP20190243A1 (ar) 2019-10-13
US10828365B2 (en) 2020-11-10
CL2019002897A1 (es) 2020-03-06
IL269791B (en) 2022-07-01
JP2024150751A (ja) 2024-10-23
CA3059364A1 (en) 2018-10-18
MY207509A (en) 2025-02-28
TN2019000289A1 (en) 2021-05-07
JP2020516647A (ja) 2020-06-11
KR20190140956A (ko) 2019-12-20
JP2023099233A (ja) 2023-07-11
BR112019021482A2 (pt) 2020-05-12
JP2025170430A (ja) 2025-11-18
AU2025204735A1 (en) 2025-07-17
US20180296669A1 (en) 2018-10-18
KR20240070727A (ko) 2024-05-21
WO2018191479A1 (en) 2018-10-18
US20210052726A1 (en) 2021-02-25
PE20200484A1 (es) 2020-03-03
EP3609917A1 (en) 2020-02-19
PH12019502331A1 (en) 2020-09-28
US20250032608A1 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
JP7330896B2 (ja) 抗ｔｓｌｐ抗体による喘息治療
EP2152290B1 (en) Methods for administering anti-il-5 antibodies
Menzella et al. Tailored therapy for severe asthma
EP2627673B1 (en) Therapies for improving pulmonary function
US20180319889A1 (en) Method and medicament for treating airway and/or lung diseases
TW202304980A (zh) 經修飾的抗ｔｓｌｐ抗體
TW202144004A (zh) 人抗tslp 抗體之配製物及其使用方法
US20230073888A1 (en) Treatment of atopic dermatitis with anti-tslp antibody
TW202509066A (zh) 用抗ｔｓｌｐ抗體治療皮質類固醇依賴性氣喘
AU2024274293A9 (en) Treatment of corticosteroid dependent asthma with anti-tslp antibody
TW202544036A (zh) 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病
KR20250140101A (ko) 항-tslp 항체를 이용한 만성 비부비동염의 치료
WO2025221247A1 (en) Treatment of eosinophilic esophagitis with anti-tslp antibody
Hammad et al. Immunotherapy for asthma
HK1188603A (en) Therapies for improving pulmonary function
HK1188603B (en) Therapies for improving pulmonary function

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221007

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20221109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230626

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230809

R150 Certificate of patent or registration of utility model

Ref document number: 7330896

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150